Antiplatelet Medications in ACS


Personalized Approach to Selecting Antiplatelet Drugs Improves Outcomes

ORLANDO (Mar 11, 2018) - Patients with acute coronary syndrome experienced a substantially lower rate of heart attack, stroke, death from cardiovascular causes and major bleeding at 12 months if genetic information was used to inform the selection of their antiplatelet medication in a study presented at the American College of Cardiology’s 67thAnnual Scientific Session.

Clinical Trial Perspective: Optimizing Crossover From Ticagrelor to Clopidogrel in Patients with Acute Coronary Syndrome (CAPITAL OPTICROSS)

Dual anti-platelet therapy (DAPT) with aspirin and a P2Y12 inhibitor reduces recurrent ischemic events in patients with acute coronary syndrome and is recommended by guidelines for patients treated with either an early invasive or ischemia-guided strategy.1,2 For initial therapy, either clopidogrel or ticagrelor are the preferred options, with prasugrel also an option at the time of percutaneous coronary intervention in some patients.

ESC Focused Update on Dual Antiplatelet Therapy in Coronary Artery Disease published today

Barcelona, Spain – 26 Aug 2017: The first ESC Focused Update on Dual Antiplatelet Therapy in Coronary Artery Disease is published online today in European Heart Journal, (1) and on the ESC website. (2) The document was developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS).

Antiplatelet Therapy in Acute Coronary Syndrome

Acute coronary syndrome (ACS) is a term used to encompass unstable angina (UA) and myocardial infarction (MI) with or without electrocardiographic (ECG) evidence of ST-segment elevation. Antiplatelet therapy has formed the backbone of ACS management for decades and the drug class continues to evolve as novel agents with increasingly efficacious antiplatelet actions are identified.

Contemporary Antiplatelet Strategies in the Treatment of STEMI using Primary Percutaneous Coronary Intervention

Antiplatelet Therapy
Current guidelines support the early administration of oral antiplatelet agents upstream of angiographic assessment and intervention.1 Aspirin is commonly given by the first medical contact and additional oral antiplatelet drugs are administered on arrival in hospital (see Figure 1).

Percutaneous Coronary Intervention in Patients Who Have an Indication for Oral Anticoagulation – an Evidence-based Approach to Antithrombotic Therapy

Patients who undergo coronary artery stenting require dual antiplatelet therapy (DAPT) in order to reduce their risk of stent thrombosis. Long-term oral anticoagulation (OAC) is indicated for the primary and secondary prevention of thrombotic events in patients with atrial fibrillation (AF), mechanical heart valves, intra-cardiac thrombus, venous thromboembolic disease and some hypercoagulable states.